MARKET

CCXI

CCXI

Chemocentryx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.41
-0.95
-4.25%
After Hours: 21.18 -0.23 -1.07% 17:42 05/24 EDT
OPEN
22.11
PREV CLOSE
22.36
HIGH
22.23
LOW
21.18
VOLUME
1.03M
TURNOVER
0
52 WEEK HIGH
42.16
52 WEEK LOW
9.53
MARKET CAP
1.52B
P/E (TTM)
-10.6831
1D
5D
1M
3M
1Y
5Y
ChemoCentryx Announces Presentation At The Society For Investigative Dermatology Meeting Highlighting The Role Of Tunnels In Driving Ongoing Disease In Hidradenitis Suppurativa
ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa -- Supports plans to advance
Benzinga · 6d ago
ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa
-- Supports plans to advance TAVNEOS®(avacopan) into Phase III development for the treatment of patients with most severe form of hidradenitis suppurativa, Hurley Stage III -- SAN CARLOS, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq...
GlobeNewswire · 6d ago
ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference
SAN CARLOS, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 2...
GlobeNewswire · 05/16 12:30
ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated Vasculitis
SAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming presentations at three key medical conferences that will highlight findings from the pivotal Phase III ADVOCATE trial that supported the appro...
GlobeNewswire · 05/11 12:30
92 Biggest Movers From Friday
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the commercialization of space technologies and services.
Benzinga · 05/09 10:27
ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates
ChemoCentryx (CCXI) posts a wider-than-anticipated Q1 loss and a revenue lag. However, product sales of CCXI's recently approved drug Tavneos grow five-fold from the previous quarter's levels.
Zacks · 05/06 19:38
55 Stocks Moving In Friday's Mid-Day Session
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 24.4% to $7.50. Swvl Holdings 13D Filing from investor Ahmed Sabbah showed a new 6.4% stake in the company.
Benzinga · 05/06 16:00
ChemoCentryx surges 15% despite top and bottom lines quarterly misses
Shares of ChemoCentryx (NASDAQ:CCXI) are trading 15% higher on Friday despite Q1 2022 results released after the closing bell Thursday that missed on the top and bottom lines. Today's upside could be
Seekingalpha · 05/06 15:50
More
No Data
Learn about the latest financial forecast of CCXI. Analyze the recent business situations of Chemocentryx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
37.50%Buy
12.50%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CCXI stock price target is 76.57 with a high estimate of 106.00 and a low estimate of 52.00.
High106.00
Average76.57
Low52.00
Current 21.41
EPS
Actual
Estimate
-0.46-0.35-0.23-0.12
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 238
Institutional Holdings: 58.29M
% Owned: 81.87%
Shares Outstanding: 71.19M
TypeInstitutionsShares
Increased
67
6.98M
New
23
1.98M
Decreased
59
3.51M
Sold Out
35
2.52M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.78%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Chairman/Chief Executive Officer/President/Director
Thomas Schall
Chief Financial Officer/Executive Vice President/Chief Administrative Officer/Secretary/Director
Susan Kanaya
Chief Operating Officer/Executive Vice President
Tausif Butt
Executive Vice President/Director
Rita Jain
Treasurer
Markus Cappel
Lead Director/Independent Director
Thomas Edwards
Independent Director
Joseph Feczko
Independent Director
Henry McKinnell
Independent Director
Geoffrey Parker
Independent Director
James Tyree
No Data
No Data
About CCXI
ChemoCentryx, Inc. is a biopharmaceutical company that focuses on the development and commercialization of medications targeting inflammatory disorders, autoimmune diseases and cancer. Its drug candidates are designed to selectively block a specific chemoattractant receptor, leaving the rest of the immune system intact. The Company's lead drug candidate Avacopan is a potential first-in-class, an orally-administered molecule that targeted mode of action in the treatment of antineutrophil cytoplasmic antibodies (ANCA) vasculitis and other complement-driven autoimmune and inflammatory diseases. The Company is also developing Avacopan for the treatment of severe (Hurley stage III) hidradenitis suppurativa (HS). Its CCX559 is an orally administered inhibitor for programmed death protein one/programmed death-ligand 1 (PD-1/PD-L1), which are developing for the treatment of various cancers.

Webull offers kinds of ChemoCentryx Inc stock information, including NASDAQ:CCXI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CCXI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CCXI stock methods without spending real money on the virtual paper trading platform.